237 related articles for article (PubMed ID: 29196119)
1. Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study.
Jansen RB; Christensen TM; Bülow J; Rørdam L; Holstein PE; Jørgensen NR; Svendsen OL
J Diabetes Complications; 2018 Feb; 32(2):164-170. PubMed ID: 29196119
[TBL] [Abstract][Full Text] [Related]
2. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes.
Petrova NL; Foster AV; Edmonds ME
Diabet Med; 2005 Jun; 22(6):756-61. PubMed ID: 15910628
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of calcaneal bone mineral density in acute Charcot osteoarthropathy.
Petrova NL; Edmonds ME
Diabetes Care; 2010 Oct; 33(10):2254-6. PubMed ID: 20628091
[TBL] [Abstract][Full Text] [Related]
4. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in diabetes mellitus patients with and without a Charcot foot.
Christensen TM; Bülow J; Simonsen L; Holstein PE; Svendsen OL
Clin Physiol Funct Imaging; 2010 Mar; 30(2):130-4. PubMed ID: 20089075
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.
Jude EB; Selby PL; Burgess J; Lilleystone P; Mawer EB; Page SR; Donohoe M; Foster AV; Edmonds ME; Boulton AJ
Diabetologia; 2001 Nov; 44(11):2032-7. PubMed ID: 11719835
[TBL] [Abstract][Full Text] [Related]
7. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy.
Gough A; Abraha H; Li F; Purewal TS; Foster AV; Watkins PJ; Moniz C; Edmonds ME
Diabet Med; 1997 Jul; 14(7):527-31. PubMed ID: 9223389
[TBL] [Abstract][Full Text] [Related]
8. Foot bone mass and analysis of calcium metabolism in diabetic patients affected by severe neuropathy.
Barbaro D; Orsini P; Lapi P; Turco A; Pasquini C
Minerva Endocrinol; 2008 Dec; 33(4):283-8. PubMed ID: 18923365
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus.
Rizzo P; Pitocco D; Zaccardi F; Di Stasio E; Strollo R; Rizzi A; Scavone G; Costantini F; Galli M; Tinelli G; Flex A; Caputo S; Pozzilli P; Landolfi R; Ghirlanda G; Nissim A
Diabetes Metab Res Rev; 2017 Feb; 33(2):. PubMed ID: 27454862
[TBL] [Abstract][Full Text] [Related]
10. Markers of Local Inflammation and Bone Resorption in the Acute Diabetic Charcot Foot.
Jansen RB; Christensen TM; Bülow J; Rørdam L; Jørgensen NR; Svendsen OL
J Diabetes Res; 2018; 2018():5647981. PubMed ID: 30155488
[TBL] [Abstract][Full Text] [Related]
11. Persistent inflammation with pedal osteolysis 1year after Charcot neuropathic osteoarthropathy.
Sinacore DR; Bohnert KL; Smith KE; Hastings MK; Commean PK; Gutekunst DJ; Johnson JE; Prior FW
J Diabetes Complications; 2017 Jun; 31(6):1014-1020. PubMed ID: 28254346
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy.
Petrova NL; Dew TK; Musto RL; Sherwood RA; Bates M; Moniz CF; Edmonds ME
Diabet Med; 2015 Feb; 32(2):267-73. PubMed ID: 25251588
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of the acute Charcot foot in diabetes.
Rudrappa S; Game F; Jeffcoate W
Diabet Med; 2012 Jun; 29(6):819-21. PubMed ID: 22587408
[TBL] [Abstract][Full Text] [Related]
14. Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density.
Herbst SA; Jones KB; Saltzman CL
J Bone Joint Surg Br; 2004 Apr; 86(3):378-83. PubMed ID: 15125125
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory osteolysis in diabetic neuropathic (charcot) arthropathies of the foot.
Sinacore DR; Hastings MK; Bohnert KL; Fielder FA; Villareal DT; Blair VP; Johnson JE
Phys Ther; 2008 Nov; 88(11):1399-407. PubMed ID: 18801857
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects on the progress of neuropathy after diabetic Charcot foot: an 8.5-year prospective case-control study.
Jansen RB; Møller Christensen T; Bülow J; Rørdam L; Holstein PE; Svendsen OL
BMC Res Notes; 2018 Feb; 11(1):140. PubMed ID: 29458435
[TBL] [Abstract][Full Text] [Related]
17. Normal blood flow response and vasomotion in the diabetic Charcot foot.
Shapiro SA; Stansberry KB; Hill MA; Meyer MD; McNitt PM; Bhatt BA; Vinik AI
J Diabetes Complications; 1998; 12(3):147-53. PubMed ID: 9618070
[TBL] [Abstract][Full Text] [Related]
18. Mortality and complications after treatment of acute diabetic Charcot foot.
Jansen RB; Jørgensen B; Holstein PE; Møller KK; Svendsen OL
J Diabetes Complications; 2018 Dec; 32(12):1141-1147. PubMed ID: 30301593
[TBL] [Abstract][Full Text] [Related]
19. Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus.
Das L; Rastogi A; Jude EB; Prakash M; Dutta P; Bhansali A
PLoS One; 2021; 16(11):e0259224. PubMed ID: 34748565
[TBL] [Abstract][Full Text] [Related]
20. Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy.
El Oraby HA; Abdelsalam MM; Eid YM; El Hilaly R; Marzouk HA
Curr Diabetes Rev; 2019; 15(5):395-401. PubMed ID: 29992889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
